Related Experiment Videos
Reduced nitric oxide levels in acromegaly: cardiovascular implications
Vanessa Ronconi1, Gilberta Giacchetti, Barbara Mariniello
1Division of Endocrinology, Department of Internal Medicine, Università Politecnica delle Marche, Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Ancona, Italy.
Blood Pressure
|August 30, 2005
Summary
Acromegaly patients show significantly reduced nitric oxide (NO) production due to lower endothelial NO synthase (eNOS) expression. This reduction in NO may contribute to cardiovascular issues in acromegaly.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Molecular Biology
Background:
- Acromegaly, caused by excess growth hormone (GH) and insulin-like growth factor-1 (IGF-1), is linked to significant cardiovascular alterations.
- Endothelial dysfunction is a suspected mechanism, with nitric oxide (NO) playing a crucial role in vascular health.
Purpose of the Study:
- To investigate the impact of elevated GH and IGF-1 on the NO pathway in acromegaly.
- To determine the role of NO in the cardiovascular changes observed in acromegalic patients.
Main Methods:
- Compared platelet NO levels and endothelial NO synthase (eNOS) expression in 13 acromegalics and 12 controls.
- Measured NO in platelet supernatants and eNOS protein via Western blot.
Main Results:
- Acromegalic patients exhibited significantly reduced platelet NO concentrations (p<0.0001) and lower eNOS protein levels (p<0.0001).
- Platelet NO levels inversely correlated with GH (p=0.03), IGF-1 (p=0.04), and disease duration (p=0.04).
Conclusions:
- This study is the first to demonstrate reduced platelet NO due to decreased eNOS expression in acromegaly.
- Reduced NO levels, linked to GH/IGF-1 excess, likely contribute to the vascular pathology in acromegaly.